Our data support the hypothesis that deficient insulin signaling may represent a critical contributing factor in the acceleration of β-amyloidogenesis during the progression of sporadic AD and thus may be an important therapeutic target in AD treatments. This evidence concerns the gene INS and Alzheimer disease.